Lerochol (lerodalcibep-liga), a once-monthly self-administered PCSK9 inhibitor, is now commercially available as adjunctive LDL-C-lowering therapy for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

A single-institution case series of 13 biopsy-proven hydroxychloroquine cardiomyopathy patients documented variable outcomes after drug cessation, ranging from full functional recovery to progression requiring advanced heart failure therapies.

A Swedish national cohort analysis linked bereavement to elevated incident cardiovascular disease risk before and during the COVID-19 pandemic, with the strongest pandemic-period association following partner loss.

First-line pulsed field catheter ablation outperformed antiarrhythmic drug therapy for rhythm control at one year in patients with persistent atrial fibrillation, with similar serious adverse event rates.

ACC, AHA, and HRS jointly updated the 2015 advanced training statement for clinical cardiac electrophysiology, adding new required competencies and revised procedural benchmarks for fellowship training.

A 23-year-old woman with bilateral blurry vision, floaters, and a history of premature birth presented with exudative retinopathy and vascular features overlapping multiple inherited and acquired retinal disorders.